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Abstract
Integration of the viral genome into host cell
chromatin is a pivotal and unique step in the
replication cycle of retroviruses, including HIV.
Inhibiting HIV replication by specifically blocking the
viral integrase enzyme that mediates this step is an
obvious and attractive therapeutic strategy. After
concerted efforts, the first viable integrase inhibitors
were developed in the early 2000s, ultimately leading
to the clinical licensure of the first integrase strand
transfer inhibitor, raltegravir. Similarly structured
compounds and derivative second generation
integrase strand transfer inhibitors, such as elvitegravir
and dolutegravir, are now in various stages of clinical
development. Furthermore, other mechanisms aimed
at the inhibition of viral integration are being
explored in numerous preclinical studies, which
include inhibition of 3’ processing and chromatin
targeting. The development of new clinically useful
compounds will be aided by the characterization of
the retroviral intasome crystal structure. This review
considers the history of the clinical development of
HIV integrase inhibitors, the development of antiviral
drug resistance and the need for new antiviral
compounds.
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Review
Early integrase inhibitors
HIV integrase (IN) is pivotal in the viral replication
cycle as it catalyzes the insertion of the reverse tran-
scribed viral genome into host chromatin. Integrase cat-
alyzes two distinct steps, 3’ processing and strand
transfer. During 3’ processing, integrase excises a
dinucleotide from the 3’ terminus of viral cDNA. This
3’-processed viral DNA is then covalently linked to host
DNA during strand transfer [1]. This unique process
has always been considered a viable drug target, which
several early studies attempted to exploit [2]. Early inte-
grase inhibitors (INIs) included peptides [3,4], nucleo-
tides [5] and DNA complexes [6] as well as small
molecules derived either from natural products [5] or by
rational drug design strategies [4,7]. Even though some
of these compounds advanced into preclinical trials,
further clinical development was always curtailed due to
in vivo toxicity and/or non-specific off-target effects.
More detailed reviews on the development of early INIs
have been published [2,4,8].
For any inhibitor to be considered useful as an anti-
viral in combination therapy for HIV, selectivity (such
as for IN) that is distinct from effects on other targets
(such as RT and protease) needs to be proven. The 4-
aryl-2,4-diketobutanoic acid inhibitors containing a dis-
tinct diketo acid moiety (DKA) were identified in 2000
by Merck investigators from a screen of 250,000 com-
pounds, and for a time were the only biologically vali-
dated INIs [9]. Their antiviral activity in cell culture was
mitigated by the development of resistance mutations in
the IN protein, thereby confirming their mode of action
[9]. These compounds, exemplified by L-731988 [10],
were found to inhibit strand transfer with much higher
potency (half-inhibitory concentration (IC50) = 80 nM)
than 3’ prime processing (6 μM) [9], and they were thus
referred to as integrase strand transfer inhibitors
(INSTIs). IN, like most nucleotidyltransferase enzymes,
requires two divalent cations bound at the active site for
activity; Mg
2+ is likely used in vivo, although Mn
2+ is
used in some in vitro assays [11]. Most INSTIs that
have been described, including DKA compounds, inhibit
IN by chelation of bound cations in a dose-dependent
manner [12]. The crystal structure [13] of IN bound to
the prototype DKA, 1-(5-chloroindol-3-yl)-3-hydroxy-3-
(2H-tetrazol-5-yl)-propenone (5-CITEP) [14] provided
structural evidence for DKA-IN binding interactions.
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proximity to the evolutionarily conserved D64 D116
E152 motif of IN, also providing valuable structural con-
firmation of the IN active site [13]. Subsequent varia-
tions of DKAs based on the 5-CITEP backbone led to
increased potency, specificity, tolerability and bioavail-
ability. This, in turn, led to the first clinically tested INI
(S-1360). Despite an initially good pharmacological and
pharmacokinetic profile in animal models, S-1360 in
initial human trials was found to be rapidly cleared
through glucuronidation [15] and its development was
curtailed.
First generation clinically approved integrase inhibitors
Raltegravir
Optimization of lead compounds including L-31988 and
L-870812 by Merck pharmaceuticals led to the develop-
ment of raltegravir (RAL; Isentress, MK-0518) (Figure
1), which in 2007 became the first (and currently only)
INI approved for treatment in both antiretroviral (ARV)
naïve and treatment-experienced patients [16]. RAL was
shown in multiple trials, such as BENCHMRK, to
achieve efficient viral load suppression in ARV-experi-
e n c e dp a t i e n t sw h e ni n c l u d e di na no p t i m i z e db a c k -
ground ARV regimen [17]. In the BENCHMRK trials,
57% of patients achieved plasma levels of HIV-1 RNA <
50 copies/mL after 97 weeks of therapy, whereas only
26% of the placebo group, treated with optimized back-
ground regimen (OBR) drugs, achieved viral suppres-
sion. The efficacy of RAL relative to other ARVs has
been modeled in cell culture and has been shown to be
owing to the activity of INIs at later stages in the viral
replication cycle than either viral entry or reverse tran-
scription inhibitors: they are therefore able to inhibit
replication in a larger proportion of productively
infected cells [18]. In another study of patients with
multidrug-resistant viruses with a median ARV treat-
ment experience of 9 years, a RAL-containing regimen
yielded higher viral load suppression than a regimen
containing placebo when combined with OBR [19]. RAL
has a favorable toxicity profile and does not appear to
have a high propensity for clinically relevant drug-drug
interactions [11], except for minor induction of the glu-
curonidation enzyme UGT1A1 responsible for RAL
elimination [20]. Interactions with drugs such as rifam-
pin may lead to modest decreases in RAL half-life and
blood concentration after 12 hours (C12hr). Predictably,
other UGT1A1 inhibitors, such as atazanavir, have been
shown to exert a modest but not clinically relevant
extension of C12hr levels for RAL. RAL has been shown
to have high bioavailability and is dosed twice daily at
400 mg/mL due to its C12hr of 142 nM [21]. Studies to
simplify RAL dosage to 800 mg once daily, boosted or
unboosted by the UGT1A1 inhibitor atazanavir, have
not yielded significant promise [22-24].
Despite the high effectiveness of RAL for first-line and
salvage therapy, resistance mutations can reduce the
susceptibility of the virus to INIs. The occurrence of
single point mutations that confer high-level resistance
(fold change (FC) > 5) to INIs have shown that RAL has
a modest genetic barrier to resistance development. To
date, three major resistance pathways involving non-
polymorphic residues have been extensively described
and characterized for RAL; E92QV/N155H, T97A/
Y143CHR and G140CS/Q148HKR [25,26]. Although
these three pathways have been shown to arise sepa-
rately, some recent reports suggest that they may be
linked. The G140S/C and E92Q/V mutations by them-
selves impart greater than five- to ten-fold resistance to
RAL [27], but usually appear only after the N155H and
Q148HKR mutations [28], leading to a FC > 100 for the
combined mutations. In addition to these major resis-
tance mutations, several polymorphic and non-poly-
morphic residues have been identified that impart a
greater than five-fold resistance to RAL. Some of these,
such as T66I/L, have been shown to act synergistically
with pre-existing major resistance mutations [29]. All
major INI resistance mutations have a major impact on
both IN activity and viral replication capacity [30]. The
result is a swift reversion to wild-type virus in patients
soon after therapy with INIs is withdrawn [31].
It has been suggested that patients without a history
of nucleoside reverse transcriptase inhibitor (NRTI)-
associated resistance may have an increased barrier for
the occurrence of resistance to RAL compared with
patients with resistance to non-NRTIs, such as nevira-
pine and efavirenz (EFV) [32]. Most reported virologic
failures due to RAL-resistance mutations have occurred
in patients harboring NRTI-resistant viruses or in
patients at increased risk of virologic failure [33]. This
was highlighted in the SWITCHMRK1 and 2 phase III
trials in patients undergoing salvage therapy with lopina-
vir, a protease inhibitor, and who switched from lopina-
vir (LPV) to RAL, despite having undetectable viremia.
The results showed that 84.4% of those who switched to
RAL (n = 353) maintained undetectable levels of viremia
compared to > 90% in the treatment group who did not
switch (n = 354). Thus, this study failed to establish
non-inferiority of RAL to LPV in the treatment of ARV-
experienced individuals with HIV with undetectable vir-
emia [33]. Of the 11 patients who experienced virologic
failure with HIV-1 RNA levels > 400 copies/mL, eight
harbored RAL-resistance mutations [34].
Elvitegravir
Elvitegravir (EVG) (GS-9137) is not a DKA but a mono-
keto acid resulting from early modification of the DKA
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This work resulted in a group of 4-quinolone-3-glyoxylic
acids, all of which had a single pair of coplanar ketone
and carboxylic groups and retained high specificity for
and efficacy against the strand transfer reaction similar
to DKA compounds [36]. EVG, now being developed by
Gilead Sciences, has been shown to have an in vitro
IC50 of 7 nM against IN and an antiviral (90% effective
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Figure 1 Clinically relevant or promising HIV integrase inhibitor compound structures.
aBased on nomenclature from [109];
bstructure of
BI-C, a precursor to BI 224436.
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presence of normal human serum [37]. EVG displayed
approximately 30% bioavailability in dogs and rats with
maximal plasma concentrations being achieved 0.5 to 1
hour post dose [37]. In clinical trials, EVG was found to
be well tolerated and efficacious [38]. Pharmacokinetic
boosting with ritonavir (RTV) was found to result in
improved dose-dependency [39].
T h ec y t o c h r o m ep 4 5 0e n z y m eC Y P 3 A 4 / 5i st h ep r i -
mary metabolizing enzyme for EVG, followed by glucur-
onidation by UGT1A1/3 [39]. Thus, the bioavailability
and clearance of EVG was found to be favored when
EVG was dosed in combination with CYP3A4/5 inhibi-
tors [11,39,40]. The CYP3A4/5 inhibitor, RTV, was
found to cause an approximate 20-fold increase in the
area under the curve and to extend elimination half-life
from three to ten hours [41]. In a phase II trial of ARV-
naïve patients (n = 48) starting initial therapy on an
OBR of tenofovir/emtricitabine (TDF/FTC), the co-
administration of EVG with a novel pharmacokinetic
booster, cobicistat, in a single tablet formulation resulted
in undetectable viremia in 90% of patients after 48
weeks compared with 83% of patients who received
TDF/FTC/EFV [42]. In a Phase IIb study, RTV-boosted
EVG was non-inferior to the RTV-boosted protease
inhibitors darunavir and tipranavir when used in combi-
nation with other drugs [43].
A major drawback to the clinical uptake of EVG,
despite it being a once-daily drug, may be that it shares
a moderate genetic barrier to INI resistance with RAL
and that extensive cross-resistance exists between the
two compounds. The RAL signature mutations N155H,
Q148H/R/K and G140A/C/S, as well as associated
accessory mutations, were selected by EVG in culture
[44] and in patients [33,45]. This precludes the use of
EVG to treat most RAL-resistant viruses. The only
major RAL-associated mutations not selected by EVG
wereY143C/R/H and subsequent studies showed that
viruses containing Y143C/R/H remained susceptible to
EVG [46]. In addition to RAL-associated resistance
mutations, EVG selected for other mutational pathways.
T66I did not confer high-level resistance to RAL [44],
but conferred a > 10-fold resistance to EVG, while a
T66R mutation conferred > 10-fold resistance to RAL
and > 80-fold resistance to EVG [47,48]. The T66I
mutation is associated with a series of accessory muta-
tions, including F121Y, S153Y and R263K; the latter two
have not been associated with RAL-resistance [49].
AF121Y mutation has been selected with RAL and con-
fers high-level resistance to this compound, but has not
yet been identified in the clinic [47]. Other clinically
selected EVG mutations are S147G, which confers >
eight-fold resistance to EVG but does not affect suscept-
ibility to RAL [47]. Other in vitro EVG selections
resulted in several high resistance mutations that have
yet to be clinically validated, such as P145S, Q146P and
V151A/L [47]. The V151L mutation confers an approxi-
mate eight-fold cross-resistance to RAL and has been
identified in a single patient treated with RAL [50].
Second generation integrase inhibitors
MK-2048
The discovery of a low-to-moderate genetic barrier of
resistance with first generation INIs led to efforts to
produce second generation INSTIs with activity against
RAL-resistant viruses. Optimization of tricyclic 10-
hydroxy-7,8-dihydropyrazinopyrrolopyrazine-1,9-dione
compounds led to the development of MK-2048 [51]
(Figure 1), which demonstrates a EC95 <5 0n Mw h e n
assayed in 50% human serum and possesses a favorable
pharmokinetic profile in dogs and rats [52]. MK-2048
was subsequently shown in tissue culture and biochem-
ical assays to be effective against RAL- and EVG- resis-
tant viruses [51-55], with only slightly diminished
effectiveness against viruses containing at least two of
the following mutations: E138K, G140S and Q148R
[51-55]. Selection studies in culture with MK-2048 did
not select for previously recognized mutations but
instead selected a novel substitution at position G118R
that, in concert with E138K, conferred approximately
eight-fold resistance to MK-2048 [56]. Despite its favor-
able resistance profile, MK-2048 has a poor pharmacoki-
netic profile and its clinical development has been
arrested. However, it has potential as a candidate micro-
bicide for prevention of HIV infection [57]. It continues
to be studied as a prototype second generation INI and
has also recently shown effectiveness in the treatment of
human T-lymphotropic virus type 1 in culture without
causing significant toxicity in target cells [58].
Dolutegravir
Dolutegravir (DTG) (S/GSK 1349572) is currently in
phase III clinical trials (for structure, see Figure 1). It
was discovered at Shionogi Pharmaceuticals in Japan
and is now being developed by a Shiniogi-ViiV Health-
care-GlaxoSmithKline joint venture [59,60]. DTG is a
promising HIV INI candidate that specifically inhibits
the strand transfer reaction with recombinant purified
integrase [60]. Inhibition of the integrase strand transfer
reaction by DTG has been confirmed in studies with
live virus, which demonstrated an accumulation of 2-
long terminal repeat (2-LTR) circles in treated cells at
DTG concentrations < 1,000-fold of those that caused
cell toxicity [61,62]. DTG also demonstrated efficacy
against most viral clones resistant to RAL and EVG and
against clinical isolates of HIV-1 and HIV-2, although
some viruses containing E138K, G140S or R148H muta-
tions possessed diminished susceptibility to DTG
[60,63-65]. Double mutants containing combinations of
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this was favorable when compared to RAL, which
yielded a FC of > 330 and > 140, respectively. In vitro
combination antiviral studies showed that DTG did not
increase toxicity when used in combination, but had a
synergistic effect with each of EFV, nevirapine, stavu-
dine, abacavir, LPV, amprenavir and enfuvirtide as well
as an additive effect in combination with maraviroc. The
hepatitis B virus drug adefovir and the hepatitis C virus
drug ribavirin had no effect on the efficacy of DTG [65],
allowing for its potential use in treating co-infections.
The pharmacokinetic profile of DTG allows once-daily
dosing without pharmacokinetic boosting. This is based
on a long unboosted half-life (13 to 15 hours) with
trough levels of DTG being much higher than the in
vitro IC90 [66]. The side-effects of DTG in volunteers
with HIV infection were similar to those of placebo in
phase I clinical trials [66].
Phase IIa randomized double blind trials provided vital
evidence of the anti-HIV effect and potency of DTG
[67,68]. Notably, 35 ARV-experienced INI-naïve
patients, who were not receiving therapy, and whose
plasma HIV-1 RNA levels ranged from 3.85 to 5.54 log
copies/mL, received once-daily doses of 2 mg, 10 mg or
50 mg DTG or placebo for 10 days. More than 90% of
patients who received DTG, irrespective of dose, had a
decline in viral load to < 400 copies/mL while 70% of
patients in the 50 mg arm achieved undetectable vire-
mia. In contrast, the placebo group showed an average
increase in viremia. No serious adverse effects were
reported in this trial, with headaches and pharyngolar-
yngeal pain being the most commonly reported conse-
quence [67].
In the SPRING-1 double blind dose-ranging phase II
trials, 205 ARV-naïve patients with HIV, with CD4
+
cells > 200 cells/mm
3 and HIV-1 RNA > 1,000 copies/
mL, were treated once daily with DTG (n = 155) at10
mg, 25 mg or 50 mg doses or 600 mg EFV (n = 50)
combined with background therapy of TDF/FTC or aba-
cavir/3TC [69]. More than 90% of all participants in the
DTG arm had undetectable viremia after 24 weeks of
treatment, establishing the non-inferiority of DTG to
EFV in an NRTI or non-NRTI background and also
showing that DTG was at least as safe as EFV.
No primary INI resistance mutations have yet been
reported for DTG either in culture or in the clinic. Tis-
sue culture selection studies over 112 weeks identified,
in order of appearance, viruses harboring T124S/S153F,
T124A/S153Y, L101I/T124A/S153F and S153Y by week
84. Although these mutations persisted throughout
serial passaging, they did not confer high-level resistance
to DTG [65]. Position 124 of IN is modestly poly-
morphic and S153F/Y had previously been described in
EVG selection studies [70]. Despite an apparently high
genetic barrier for resistance, selection, recent tissue cul-
ture and biochemical studies report that a R263K muta-
tion in IN may confer modest resistance to DTG [71].
It has been suggested that DTG enjoys a high barrier
for resistance due to a tighter binding of DTG to IN
compared to RAL and EVG [72]. Assays also showed
that DTG exhibited tighter binding and had a longer
dissociative half-life from IN than either RAL or EVG
[73].
In this model, a direct relationship existed between
the half-life of binding and the inhibitory potential of
INIs when the binding half-life (t1/2) was below 4 hours.
A > 3 FC in regard to drug resistance, relative to the
wild-type, was observed when the t1/2 dropped below 1
hour [72]. In assays with wild-type enzymes, the t1/2 of
DTG, RAL and EVG were 71, 8.8 and 2.7 hours, respec-
tively. The fact that RAL and EVG have a shorter t1/2
than DTG suggests that resistance mutations that affect
binding of RAL and EVG might also be more likely to
compromise antiviral potency. As an example, the
Y143CHR mutations have been shown to compromise
interactions between IN and RAL but not those between
IN and DTG or between IN and EVG [74]. This is
further supported by data on mutations that have been
shown to significantly reduce t1/2, E92Q/N155H, E138K/
Q148R and G140S/Q148R, and significantly reduce anti-
viral potency [72]. This hypothesis had been previously
suggested for MK-2048, which also has a relatively high
barrier for resistance, as it also has a slower off-rate (t1/2
= 32 hours) for IN compared to RAL (t1/2 ≥ 7.3 hours)
[73].
The use of DTG in INI-salvage therapy is being inves-
tigated in an ongoing study called VIKING. The latter is
a phase II single arm study investigating the feasibility
of replacing RAL with DTG in patients experiencing
failure due to RAL-resistant viruses [59]. Participants (n
= 27) were switched from their previous RAL-containing
regimens to receive DTG 50 mg once daily for 10 days
and were then prescribed other active drugs over a per-
iod of 23 weeks. Eighteen of the study participants had
INI- resistant viruses belonging to the Y143, Q148 and
N155 pathways prior to initiation of the study. After 10
days of DTG monotherapy, all participants harboring
viruses in the Y143 and N155 pathways attained a mean
HIV-1 RNA decrease of approximately 1.8 log copies/
mL compared with approximately 0.7 log copies/mL for
viruses harboring G140S/Q148HRK double mutations.
None of the viruses harboring Q148HRK plus two or
more additional mutations experienced a decrease of ≥
0.7 log copies/mL, indicating a degree of resistance on
the part of Q148HRK viruses to DTG. This trial none-
theless provided proof-of-principle for the use of DTG
in RAL-experienced patients infected by subtype-B
viruses harboring position Y143 and N155 mutations.
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enced patients, several serial passaging studies have
been carried out and shown that the presence of the
N155H and Y143CHR resistance did not lead to devel-
opment of additional resistance mutations under DTG
pressure nor to a substantial decrease in DTG suscept-
ibility [62,64]. In contrast, the presence of Q148HRK
mutations did lead to further mutations and > 100 FC
for DTG susceptibility relative to wild-type in subtype B
viruses [63,65]. Interestingly, Q148HRK mutations did
not affect susceptibility to DTG in HIV-1 subtype C and
HIV-2 isolates [65,75,76]. An ongoing trial termed
SPRING-2 will evaluate the use of once-daily DTG ver-
sus twice-daily RAL in treatment-naïve patients. A
Phase III trial termed SAILING will compare once-daily
versus twice-daily DTG in ARV-experienced INI-naïve
participants with HIV [77].
S/GSK-1265744
Another second generation INSTI called S/GSK-
1265744, which is a back-up drug to DTG, has been
tested in double blind randomized placebo-controlled
trials and has shown promising short-term efficacy, an
excellent pharmacokinetic profile and good tolerability
in patients with HIV [78]. Its future development is
uncertain, however, given the positive state of develop-
ment and promise of DTG.
Advances aiding integrase inhibitor discovery
Crystallization of full-length integrase
Due to the low solubility of HIV-1 IN [79,80], elucida-
tion of the full-length IN structure has never been
accomplished. The first IN partial-structure was pub-
lished in 1994 [81]; however, despite the insights
afforded by this and subsequent structures, including
the first partial IN structure complexed with an inhibi-
t o r[ 1 3 ] ,n o n eo ft h e s es t r u c t u r e sg a v eap r o p e rd e p i c -
tion of inhibitor drug interactions, IN-DNA interactions
or functional IN quaternary structures. Co-crystal struc-
tures of integrase from the lentivirus Maedi-Visna with
human LEDGF [82] suggested that the functional IN
protein might be tetrameric, consisting of a dimer of
dimers, and this further showed the necessity of obtain-
ing full-length crystal structure for proper elucidation of
IN structure, function and inhibition. In 2010, the full-
length structures of IN from the prototype foamy virus
(PFV) in complex with LTR mimetics were published
[83]. This paper provided the first glimpse into interac-
tions between IN and viral DNA and also established
the binding mode of the INSTIs RAL and EVG. A fol-
low-up publication [84] provided excellent structural
explanations for the impact of mutations at positions
92, 140, 148 and 155 on RAL and EVG susceptibility.
Thus, despite the fact that PFV is a spumavirus, only
having significant sequence identity with HIV-1 IN in
the catalytic core domain (CCD) domain, PFV IN struc-
tures could guide construction of reliable homology
models of HIV-1 IN with accurate prediction of interac-
tions between IN and INSTI [85]. Later crystallization
efforts by the same group yielded IN-DNA strand trans-
fer complexes in the presence and absence of inhibitors
[86], again providing new structural data, a better
understanding of the strand transfer process and infor-
mation on new INI discovery initiatives. Co-crystalliza-
tion studies have attributed the observed efficacy of
DTG against RAL- and EVG-resistant viruses to the
flexibility of DTG and its ability to bind to IN, even in
t h ep r e s e n c eo fm a j o rI N Ir e s i s t a n c em u t a t i o n s[ 7 4 ] .I t
remains to be seen whether PFV structures can aid in
the elucidation of non-catalytic site INIs, given major
differences that may exist distal from the IN active site.
For instance, PFV integrase does not interact with
LEDGF [87]; as such, models based on PFV may not be
able to help in the design of IN-LEDGF inhibitors.
Further insights into integration based on PFV struc-
tures are discussed in other reviews [88,89].
Quantitative structure-property and -activity relationships
The recent elucidation of the full-length PFV intasome
and strand transfer complexes have allowed for the gen-
eration of homology models of HIV-IN that can be used
to ‘train’ and score drug prototypes. There are multiple
quantitative structure-property relationships (QSPR) and
quantitative structure-activity relationships (QSAR) pro-
tocols and programs. Some of these require advanced
programming and mathematical skills, but several stand-
alone and online programs offer semi-automated drug
docking and scoring capabilities with moderate to high
accuracy. The main aim of these approaches is to allow
in silico validation and testing of prototype molecules in
order to lower the costs associated with large-scale
synthesis of non-validated compounds [90]. Typical
QSPR and QSAR protocols use a given set of conditions
that train and/or test the structures and a set of valida-
tory parameters that are then used to score the data.
Structures can then be selected for subsequent synthesis
and experimental validation [91]. Typical input takes
into account the physicochemical properties of indivi-
dual moieties on the compound, bond-length, flexibility,
lipophilicity and/or hydrophilicity, information on the
target and three-dimensional binding space. This can
generate theoretical estimations of IC50, binding affinity,
bioavailability, hepatic clearance and other parameters.
Recent work has used a molecular dynamics approach
to accurately predict potency of INSTIs based on mod-
els derived from the PFV structure [92]. A summary of
computer-based approaches for design of novel INIs
that target 3’ processing, IN multimerization, strand
transfer complex assembly and IN-host protein interac-
tions has recently been published [93]. Despite these
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bioavailability and safety prior to the synthesis and study
of novel compounds.
Next-generation strand transfer inhibitors in preclinical
development
The design of MK-0536 by Merck & Co., Inc. was based
on QSPR and QSAR that took into account the opti-
mum minimum structure necessary for activity and gen-
erated a set of potential structures that could be
synthesized and screened. MK-0536 has shown low
hepatocyte clearance values [94] and generally good
inhibition of wild-type IN and RAL-resistant IN [94,95]
but its current level of clinical development is unclear.
Other classes of compounds that block strand transfer
with high specificity at sub-nanomolar EC50sa n dl o w
toxicities are catechol-based [96], pyrimidone-based
[97-100], dihydroxypyrido-pyrazine-1,6-diones [101] and
quinolones [102,103].
Inhibiting integrase-host factor interactions
The understanding that IN takes part in a number of
interactions with host proteins and their post-transla-
tional modifications has led to the targeting of some of
these processes (reviewed in [104,105]). Separate stu-
dies have shown that sumoylation [106] and acetylation
[107] of IN occurs in vivo, leading to increased activity,
but there are currently no inhibitors of these reactions
that can specifically target IN modification without
affecting other cellular proteins [108]. The observation
that integration can be inhibited in ex vivo HIV-
infected CD4
+ T-cells of elite controllers [108] has not
yet led to the identification of a responsible cellular
factor. Currently, the most promising inhibitors target-
ing IN-host interactions disrupt the interaction
between IN and LEDGF/p75; the latter is a host pro-
tein that has been shown to be essential for tethering
the IN pre-integration complex to host chromatin and
also for the recruitment of other cellular factors to the
pre-integration complex, thereby facilitating effective
integration [109,110]. Inhibition of the LEDGF/p75-IN
interaction can seriously inhibit viral replication
[109,111]. This is supported by the recent finding that
polymorphisms in the PSIP-1 gene that codes for
LEDGF/p75 can affect rates of HIV disease progression
[112].
Allosteric inhibitors
LEDGINS LEDGINS (Figure 1) were designed as speci-
fic small molecular inhibitors of the LEDGF/p75 interac-
tion. Optimized structures within the group of 2-
(quinolin-3-yl)acetic acid derivatives co-crystallized with
LEDGF/p75-IN were shown to inhibit the LEDGF/p75-
IN interaction at submicromolar concentrations and to
inhibit strand transfer activity of IN, even in the absence
of LEDGF/p75 [109,111]. Peptides mimicking the IN
binding domain of LEDGF/p75 exhibit potent inhibition
of IN [113,114].
BI 224436 BI 224436 is a novel INI with a distinct
mode of action from more established INSTIs. It is a
non-catalytic site integrase inhibitor that, like the LED-
GINs described above, interferes with the interaction
between IN and the chromatin targeting the LEDGF/
p75 protein, yielding low nanomolar inhibition of 3’ pro-
cessing and viral replication [115]. It is not yet clear why
these two sets of allosteric inhibitors, binding in the
same pocket, should specifically inhibit different IN
activities. The profile of BI 224436 appears favorable
and it also appears to be specific, since it did not exhibit
reduced activity against any INSTI-resistant IN enzymes
[115]. This compound has now entered phase Ia clinical
trials to evaluate dosing and safety in healthy indivi-
duals. Initial reports indicate high bioavailability with
good tolerability at single doses ranging up to 200 mg.
BI 224436 also exhibited good dose-proportional phar-
macokinetics when given as a single dose of 100 mg,
and plasma levels appeared adequate to achieve a thera-
peutic effect [116]. There have been a number of recent
in-depth reviews on the subject of LEDGF/p75 targeted
INIs [111,114,117].
Dual reverse transcriptase and integrase inhibitors
The structural and functional similarities between HIV-1
IN and the RNAse-H domain of HIV-1 RT suggest the
possibility of specific yet dual targeting inhibitors of
both processes. Some early compounds that have been
found to target both enzymes are DKAs [118,119]. This
hybrid class has been comprehensively reviewed else-
where [120].
HIV diversity and integrase inhibitors
Recent reports indicate that subtype differences may
exist with regard to the development of resistance to IN
inhibitors, a phenomenon that also exists with RT inhi-
bitors [27,121,122]. Despite the fact that HIV-1 subtype
B and C wild-type IN enzymes are similarly susceptible
to clinically validated INIs [61], the presence of resis-
tance mutations may differentially affect susceptibility to
specific INSTIs [27]. Recent reports suggest that the
G118R mutation, which was previously reported to con-
fer slight resistance to MK-2048, imparts a 25-fold resis-
tance to RAL when present together with the
polymorphic mutation L74M in CRF-AG cloned patient
isolates [123]. Additionally, it is well documented that
the INI Q148RHK resistance mutations, which affect
susceptibility to DTG in HIV-1 subtype B, may not
affect the susceptibility of either HIV-1 subtype C or
HIV-2 enzymes to DTG [72].
Conclusions
The development of INSTIs has resulted in a new drug
class in the anti-HIV armamentarium. New compounds
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Page 7 of 11are being developed that possess improved resistance
profiles and pharmacokinetics. It therefore seems likely
t h a tI N S T I sw i l lb eaf u t u r es t a l w a r to fa n t i r e t r o v i r a l
therapy. These advances have been accompanied by
improved understanding of IN function that, in turn, is
leading to the identification of new molecules that can
block IN function through novel mechanisms.
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